SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech100 is drawing significant attention as investors position for the highly anticipated SpaceX IPO, with community members noting the fund's high concentration in SpaceX and Anthropic as a strategic play. Discussions are fueled by speculative reports of an imminent IPO filing and comparisons to other venture-focused funds, with participants debating the fund's premium to net asset value and the long-term potential of its private tech holdings.

The Shrimp Army

The community is actively trading SHRIMPS as part of a broader trend of animal-themed memecoins, sparking intense debate over whether it represents a legitimate high-growth opportunity or a short-lived pump-and-dump scheme. Market participants are closely watching price volatility and momentum, with many warning of the high risks associated with these rapid boom-and-bust cycles.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is generating intense debate as traders weigh aggressive corporate Bitcoin accumulation against concerns regarding share dilution and the stock's high premium. While bulls highlight the company's massive digital asset reserves as a long-term lever, bears are actively targeting the symbol's volatility and its status as a high-beta proxy for broader crypto market swings.

NKN is building the largest blockchain for network sharing.

New Kind of Network

NKN is capturing significant community attention as a potential DePIN and Web3 breakout candidate, fueled by its low market cap and the promise of its secure, decentralized nMobile communications platform. Traders are actively debating whether the asset is currently experiencing manipulative price suppression or coiling for a major move as they compare its utility and scarcity against other high-growth altcoins.

Chess Grandmaster Hans Nieman was accused of cheating during a tournament by wearing a vibrating butt plug which sent morse code for which move he should make. In response dev Ron Sijim created the Buttfish Github.   Buttfish is a github repository which explains how a vibrating butt plug could transmit morse code for chess. In this github he literally says this project is a "meme" so why not make him a memecoin.   He also has a Eth wallet listed for donations, so clearly he is crypto native  Send Buttfish Coin

Buttfish Coin

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is gaining significant community traction as supporters rally behind its long-term vision of becoming a global cryptocurrency for cannabis culture. Investors are actively discussing the project's consistent development and cultural appeal ahead of key seasonal events, viewing it as a grassroots alternative to traditional industry stocks.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing significant selling pressure as investors grapple with AI-related capital expenditure concerns and broader software sector volatility. While the community remains deeply divided between long-term bulls highlighting strong fundamental cash flows and bears pointing to a technical breakdown, intense daily price fluctuations continue to fuel speculative debates over whether the stock is a value trap or a generational buying opportunity.

Zillow Group, Inc. engages in the provision of real estate and home-related information marketplaces on mobile and the web. The company was founded by Richard N. Barton and Lloyd D. Frink in December 2004 and is headquartered in Seattle, WA.

Zillow Group Inc - Ordinary Shares - Class C

Zillow Group Inc Class C

Zillow is currently a focal point for community debate, as users weigh the impact of recent housing market data and shifting mortgage rate expectations against the platform's role in the evolving digital real estate landscape. Traders are actively monitoring potential integration opportunities and sector-wide sentiment, with much of the discussion centered on how Zillow stacks up against emerging competitors and broader housing sector challenges.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is facing scrutiny and volatility as investors weigh the company's aggressive infrastructure investment in AI against broader macroeconomic concerns, including rising energy costs and geopolitical instability. While some in the community see the current price as a buying opportunity for a long-term compounder, others remain cautious, pointing to ongoing regulatory challenges and concerns over whether recent AI spending will generate sufficient near-term returns.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is trending as investors grapple with the launch of a private-label energy drink by Costco, sparking intense community debate over potential market share loss and brand loyalty. While some traders are reacting to the negative sentiment and bearish price action, many long-term shareholders view the pullback as a buying opportunity, emphasizing that the company's core growth, international expansion, and strong brand presence remain intact despite the noise.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing

In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $58.94, denoting a +2.7% move from the preceding trading day.

Will the Recent Label Expansion of BMY's Opdivo Boost Its IO Franchise?

Bristol Myers Squibb's Opdivo expansions highlight pharma companies' push to grow oncology franchises amid rising competition and pipeline innovation.

Procyon Advisors LLC Sells 20,349 Shares of Bristol Myers Squibb Company $BMY

Procyon Advisors LLC trimmed its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 56.8% during the fourth quarter, according to the company in its most recent 13F filing with the...

E. Ohman J or Asset Management AB Buys 46,000 Shares of Bristol Myers Squibb Company $BMY

E. Ohman J or Asset Management AB boosted its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 183.2% during the fourth quarter, according to its most recent Form 13F filing with the...

<ul class="summary-bullets"><li>Founder Patrick Soon-Shiong said Abraxane from Bristol Myers Squibb could help boost immune responses when combined with the company’s cancer immunotherapy Anktiva.</li><li>Founder Patrick Soon-Shiong said Abraxane may help “expose” tumors through immune-activating signals and support macrophage activity.</li><li>Anktiva was recently added to Macau’s approved drug list and included by the National Comprehensive Cancer Network for certain bladder cancer patients.</li></ul>Shares of ImmunityBio, Inc. (IBRX)&nbsp;rose over 1% in premarket trading on Tuesday after a newly posted Phase 1 study showed its cancer therapy Anktiva is being tested alongside Bristol Myers Squibb’s Abraxane and other drugs in patients with pancreatic cancer ahead of surgery.<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> jumped nearly 11% on Monday, marking its best session in a month.<h2 class="st-heading-2">Phase 1 Trial Tests Anktiva In Pancreatic Cancer</h2>According to a new regulatory update on Monday, the open-label Phase 1 study is evaluating Anktiva in combination with the investigational agents Sotevtamab and Zabadinostat, plus the chemotherapy drugs Gemcitabine and Abraxane, in participants with borderline resectable or locally advanced pancreatic ductal adenocarcinoma.The treatment is being given before surgery, followed by tumor removal and additional immunotherapy afterward, as researchers evaluate the safety and early signals of effectiveness of the combination approach.Participants enrolled in the study will undergo endoscopic ultrasound-guided biopsies of the primary tumor within seven days before treatment begins. Samples will be used for diagnostic evaluation and stored in an approved tissue bank.<h2 class="st-heading-2">Bristol Myers’ Abraxane May Support Anktiva</h2>Soon-Shiong&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrPatrick/status/2036321510348947567">said on X</a> that Abraxane differs from older chemotherapy agents such as Taxol because it is delivered using albumin, a naturally occurring protein that helps transport the drug across blood vessel walls into the tumor microenvironment.He said the drug enters tumors through a natural transport pathway called GP60 and helps activate macrophages to attack cancer cells while also “exposing” tumors through DAMP signaling, making them easier for natural killer (NK) cells and T cells to recognize and destroy.“So it’s not that we ignore the use of chemo, it’s how we use it to activate the immune system while protecting and activating the lymphocytes with Anktiva,” Soon-Shiong said. Abraxane was originally developed by Abraxis BioScience, which Soon-Shiong founded, and is now marketed by Bristol Myers Squibb for breast, lung and pancreatic cancers.<h2 class="st-heading-2">Anktiva Platform Therapy Strategy Gains Support</h2>The development adds to ImmunityBio’s broader effort to position Anktiva as a platform immunotherapy that works alongside vaccines, checkpoint inhibitors and chemotherapy backbones across multiple cancer types rather than as a standalone treatment.Last week, Soon-Shiong pointed to&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-premarket-early-anktiva-immune-data-macau-nod-bull-case/cZ3Xl3sRILc">early immune data</a> from the first 20 participants in an Anktiva study showing increases in absolute lymphocyte counts when the therapy was used with the company’s adenovirus-based cancer vaccine. The trial has enrolled 138 patients randomized to the combination or placebo.He said baseline lymphocyte levels typically decline with age but appeared to increase with Anktiva in the early analysis, supporting the therapy’s immune-stimulating role.<h2 class="st-heading-2">Anktiva Gains Macau Listing, NCCN Backing</h2>Momentum around Anktiva has also been driven by recent regulatory developments, including its addition to&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-snap-losing-streak-anktiva-macau-drug-list/cZ3XLBrRIhU">Macau’s approved</a> drug list for bladder cancer. Anktiva now stands alongside therapies from Bristol Myers Squibb, Eli Lilly, Vertex Pharmaceuticals, Gilead Sciences and Moderna in Macau.&nbsp;In the U.S., the National Comprehensive Cancer Network (NCCN) added Anktiva with BCG as an “other recommended” option for papillary bladder cancer that no longer responds to standard BCG treatment, expanding its positioning beyond carcinoma in situ under treatment guidelines.ImmunityBio has also resubmitted its application seeking to expand Anktiva’s label to papillary bladder cancer after previously receiving a refusal-to-file letter from regulators.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for IBRX has slipped to ‘bearish’ levels over the past week from the ‘extremely bullish’ zone amid ‘low’ message volumes over the last 24-hours.<figure class="image"><img src="https://news.stocktwits-cdn.com/ibrx_ss_png_68b9bc5725.webp" alt="ibrx ss.png" width="973" height="145"><figcaption>IBRX sentiment and message volume as of March 24 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/PureLand/message/648355601">said</a> IBRX shares showed signs of steady accumulation after closing near session highs and, citing recent regulatory and guideline momentum. They expect the stock to climb toward $20 by Friday.<stembedurl>https://stocktwits.com/PureLand/message/648355601</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Dirk1969/message/648354937">said</a> IBRX is “currently the best stock with the most potential.”<stembedurl>https://stocktwits.com/Dirk1969/message/648354937</stembedurl>IBRX stock has surged nearly 250% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the ImmunityBio logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

IBRX Stock Rises Premarket: Anktiva Moves Into Pre-Surgery Pancreatic Cancer Combo Trial With Bristol Myers Drug

The comments come amid the firm’s strategy to position Anktiva as a platform immunotherapy that works along with vaccines, checkpoint inhibitors and chemotherapy.

Equity

Diversified Trust Co. Has $6.82 Million Stock Holdings in Bristol Myers Squibb Company $BMY

Diversified Trust Co. grew its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 25.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 126,336 shares of the biopharmaceutical company's stock a...

FDA Approves BMY's Opdivo Label Expansion in Classical Hodgkin Lymphoma

Bristol Myers expands Opdivo's reach with new U.S. and EU approvals in Hodgkin lymphoma, strengthening its immunotherapy leadership and growth outlook.

Can Anktiva's Label Expansion Unlock the Next Growth Phase for IBRX?

ImmunityBio bets on Anktiva label expansion to drive growth, but intense Big Pharma competition and premium valuation raise questions about its next phase.

Wealth Enhancement Advisory Services LLC Purchases 318,898 Shares of Bristol Myers Squibb Company $BMY

Wealth Enhancement Advisory Services LLC raised its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 26.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,533,355 shares of the biopharmaceutica...

Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos (mavacamten) Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26)

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of new clinical trial and real-world data for Camzyos (mavacamten) at the American College of Cardiologys (ACC) Annual Scientific...

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Current Price	$58.94
Prev Close	$57.39
Open	$57.79
Dividend Yield	4.62%
50-Day Moving Average	$58.65
Beta	0.32
Avg. Volume	13.86M
PE Ratio	17.04

52-Week High	$62.89
52-Week Low	$42.52
Market Capitalization	$120.03B
EPS (Annual)	$3.46
Price to Book	6.50
Revenue Per Employee	$1.48M

BMY
Bristol-Myers Squibb Co.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BMY News

BMYBristol-Myers Squibb Co.